1. Vasan RS, Benjamin EJ, Levy D. Prevalance, clinical features andprognosis of diastolic heart failure: an epidemiologic perspective. J AmColl Cardiol 1995;26(7):1565-1574.
2. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D.Congestive heart failure in subjects with normal versus reduced leftventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33(7):1948-1955. doi:10.1016/s0735-1097(99)00118-7
3. Anker SD, von Haehling S. Inflammatory mediators in chronicheart failure: an overview. Heart. 2004;90(4):464-470. doi:10.1136/hrt.2002.007005
4. Mann DL. Inflammatory mediators and the failing heart: past, present,and the foreseeable future.Circ Res. 2002;91(11):988-998. doi:10.1161/01.res.0000043825.01705.1b
5. Aukrust P, Ueland T, Müller F, Andreassen AK, Nordoy I, Aas H,et al. Elevated circulating levels of C-C chemokines in patientswith congestive heart failure. Circulation. 1998;97(12):1136-1143.doi:10.1161/01.cir.97.12.1136
6. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, MannDL. Cytokines and cytokine receptors in advanced heart failure: ananalysis of the cytokine database from the Vesnarinone trial (VEST).Circulation. 2001;103(16):2055-2059. doi:10.1161/01.cir.103.16.2055
7. Gibson PH, Cuthbertson BH, Croal BL, Rae D, El-Shafei H, Gibson G,et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am JCardiol. 2010;105(2):186-191.
8. Christopher PA. Diastolic heart function. In: Murphy JG, Lloyd MA(eds), Mayo Clinic Cardioloji Concise Textbook (third ed.) Mayo ClinicScientific Pres. 2008: 1087-8.
9. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral L-arginineimproves endothelial dysfunction in patients with essentialhypertension.Int J Cardiol. 2002;86(2-3):317-323. doi:10.1016/s0167-5273(02)00413-8
10. Burnett JC Jr. Coronary endothelial dysfunction in the hypertensivepatient: from myocardial ischemia to heart failure. J Hum Hypertens1997;11(1):45-49.
11. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM,Quinn MT. Localization of a constitutively active phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement byangiotensin II. Proc Natl Acad Sci USA. 1997;94(26):14483-8.
12. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F.Predictive value of elevated neutrophil-lymphocyte ratio on cardiacmortality in patients with stable coronary artery disease.Clin ChimActa 2008;395(1-2): 27-31.
13. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction anddiastolic heart failure. Annu Rev Med. 2004;55:373-94.
14. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interactionwith hemodynamic and hormonal factors. Cardiovasc Res. 1999;41(3):532-43.
15. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases bycytokines and reactive oxygen/nitrogen species in the myocardium.Heart Fail Rev. 2004;9(1):43-51.
16. Yambe M, Tomiyama H, Hirayama Y, et al. Arterial stiffening as apossible risk factor for both atherosclerosis and diastolic heart failure.Hypertens Res. 2004;27(9):625-631.
17. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolicand arterial stiffening in patients with heart failure and preservedejection fraction: implications for systolic and diastolic reservelimitations. Circulation. 2003;107(5):714-720.
18. Pirro M, Schillaci G, Savarese G, et al. Low-grade systemicinflammation impairs arterial stiffness in newly diagnosed hyper-cholesterolaemia. Eur J Clin Invest. 2004;34(5):335-341.
19. Kass DA. Ventricular arterial stiffening: integrating thepathophysiology. Hypertension. 2005;46(1):185-193.
20. Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction inhypertension. Acta Cardiol 2000;55(4):221-232.
21. Lemarie CA, Esposito B, Tedgui A, Lehoux S. Pressure inducedvascular activation of nuclear factor-kappa B: role in cell survival. CircRes 2003;93(3):207-212.
22. Renaudin C, Bataillard A, Sassard J. Partial transfer of genetichypertension by lymphoid cells in Lyon rats. J Hypertens. 1995;13(12 Pt2):1589-1592.
23. Chung NA, Beevers DG, Lip G. Effects of losartan versushydrochlorothiazide on indices of endothelial damage/dysfunction,angiogenesis and tissue factor in essential hypertension. Blood Pres2004;13(3):183-189.
24. Dörffel Y, Lätsch C, Stuhlmüller B, et al. Preactivated peripheral bloodmonocytes in patients with essential hypertension. Hypertension1999;34(1):113-117
25. Mc Eniery CM, Wilkinson IB. Large artery stiffness and inflammation.J Hum Hypertens 2005;19(7)507-509.
26. Mc Carron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM. Monocyteadhesion to cerebromicrovascular endothelial cells derived fromhypertensive and normotensive rats. Am J Physiol. 1994;267(6 Pt2):2491-2497.
27. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatorymarkers and risk of heart failure in elderly subjects without priormyocardial infarction: the Framingham Heart Study.Circulation.2003;107(11):1486-1491. doi:10.1161/01.cir.0000057810.48709.f6
28. Masiha S, Sundström J, Lind L. Inflammatory markers are associatedwith left ventricular hypertrophy and diastolic dysfunction in apopulation-based sample of elderly men and women.J Hum Hypertens.2013;27(1):13-17. doi:10.1038/jhh.2011.113
29. Horne BD, Anderson JL, John JM et al. Intermountain HeartCollaborative Study Group. Which white blood cell subtypes predictincreased cardiovascular risk? J Am Coll Cardiol 2005;45(10):1638-1643.
30. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, GurmHS. Association between admis¬sion neutrophil to lymphocyte ratioand outcomes in patients with acute coronary syndrome. Am J Cardiol2008;102(6):653- 657.
31. Fauzia Imtiaz. Neutrophil lymphocyte ratio as a measure of systemicinflammation in prevalent chronic diseases in Asian population. IntArch Med. 2012;5(1):2.
32. Demir M. The Relationship Between Neutrophil Lymphocyte Ratio andNon-dipper Hypertension. Clin Exp Hypertens. 2013;35(8):570-573.
33. Liu X, Zhang Q, Wu H et al. Blood neutrophil to lymphocyte ratio as apredictor of hypertension. Am J Hypertens. 2015;28(11):1339-1346.
34. Aydin C, Alpsoy Ş, Akyüz A et al. Could the systemic immune-inflammation index be a predictor to estimate cerebrovascular eventsin hypertensive patients? Blood Press Monit. 2022;27(1):33-38.
35. Madhur MS, Elijovich F, Alexander MR, et al. Hypertension: doinflammation and immunity hold the key to solving this epidemic? CircRes. 2021;128(7):908-933. doi:10.1161/CIRCRESAHA.121.318052
36. Boos CJ, Toon LT, Almahdi H. The relationship between ambulatoryarterial stiffness, inflammation, blood pressure dipping andcardiovascular outcomes. BMC Cardiovasc Disord. 2021;21(1):139.doi:10.1186/s12872-021-01946-2